Gene Expression Assay in the Management of Early Breast Cancer.

Gene Expression Assay in the Management of Early Breast Cancer. Curr Med Chem. 2019 Dec 05;: Authors: Caputo R, Cianniello D, Giordano A, Piezzo M, Riemma M, Trovo M, Berretta M, De-Laurentiis M Abstract The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of patients could be exposed to unnecessary treatment-related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician decision-making process and to taylor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay). PMID: 31804159 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research

Related Links:

We present the case of a 63-year-old patient that was diagnosed in another Clinic with squamous skin carcinoma, but, after complete resection in our Hospital, it was proven to be breast cancer. At diagnosis, computed tomography (CT) scan showed local disease. Adjuvant treatment, consisting in chemotherapy and radiotherapy, was administered. At the beginning of hormonal therapy, the patient had a new CT scan that showed liver and bone metastases. The patient started palliative hormonal treatment with bisphosphonates. The aim of the study was to highlight both the importance of early diagnosis and treatment and the aggressiv...
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
Breast cancer survivors who underwent chemotherapy or hormone therapy were found to be more likely to have a higher symptom burden and lower overall sense of well-being than noncancer counterparts.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
ConclusionsIn this cohort of young women, population-based cancer registry data on chemotherapy receipt was reasonably accurate and complete in comparison with insurance claims. Radiation and hormone therapy appeared to be less complete.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Conclusions: Use of the 21-gene rs assay could be a cost-effective strategy for Ontario patients with estrogen receptor-positive, her2-negative early bca and 1-3 positive lns. PMID: 31708649 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
(European School of Oncology) Patients with advanced breast cancer that has spread to the skin are likely to cause more harm than good if they use complementary therapies to treat their skin lesions. Professor Maria Jo ã o Cardoso told the Advanced Breast Cancer Fifth International Consensus Conference (ABC5) in Lisbon that there was a long list of herbal products and creams that patients often try, but many of them could delay wound healing and interfere with systemic anti-cancer treatments such as hormone therapy or chemotherapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Wiley) A woman's decision to undergo mastectomy for breast cancer relies on communication with her surgeon and, in addition, often draws on recommendations from a 'multidisciplinary team' (MDT) of doctors from different specialties such as oncology and radiology. An analysis published in the BJS found that most mastectomies in the UK are advised when tumours are large, and that some of these might have been avoided if more women had been given hormone therapy or chemotherapy to shrink the cancer before the surgery.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In this study, a Distress and Impact Thermometer was used to classify patients with adjustment disorders, depression, or major depression and suicidal ideation into a group with psychological problems and the remaining patients into a group with no psychological problems. RESULTS: Logistic regression analysis showed that only DASH was statistically significantly associated with psychological conditions (p 
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
CONCLUSION: QoL of Egyptian females with BC was influenced by several factors like age, marital status, occupation, smoking, residence, comorbidities, symptoms, grade, chemotherapy, radiation, and recurrence. PMID: 31653162 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Cancers, Vol. 11, Pages 1669: Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore Cancers doi: 10.3390/cancers11111669 Authors: Ayelet Alfasi Irit Ben-Aharon Breast cancer is the most common form of malignancy in pregnant women. The prevalence of pregnancy-associated breast cancer (PABC) is up to 0.04% of pregnancies and is expected to rise in developed countries. PABC represents a unique clinical scenario which requires a delicate balance of risks and benefits for both maternal and fetal well-being. Currently, there is paucity of data regarding the short- and long-term outcomes of in-utero e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer. Oncol Rep. 2019 Oct 07;: Authors: Naoi Y, Saito Y, Kishi K, Shimoda M, Kagara N, Miyake T, Tanei T, Shimazu K, Kim SJ, Noguchi S Abstract We previously developed a 95‑gene classifier (95GC) to classify ER‑positive/HER2‑negative/node‑negative (ER+/HER2‑/N0) breast cancer as high‑ and low‑risk. The present study aimed to devise a 95GC recurrence score (95GCRS) to estimate recurrence risk ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Genetics | Health Management | Hormonal Therapy | Hormones